Product Description: Panitumumab (ABX-EGF) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab can be used in the research of cancers, such as colon cancer[1][2][4].
Applications: Cancer-Kinase/protease
Formula: N/A
References: [1]Daniel J. Freeman, et al. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor. Mol Cancer Ther (2009) 8 (6): 1536–1546./[2]Yu Jo Chua, et al. Panitumumab. Drugs Today (Barc). 2006 Nov;42(11):711-9./[3]Efstathia Giannopoulou, et al. Autophagy: novel action of panitumumab in colon cancer. Anticancer Res. 2009 Dec;29(12):5077-82./[4]Stefan Stremitzer, et al. Panitumumab safety for treating colorectal cancer. Expert Opin Drug Saf. 2014 Jun;13(6):843-51./[5]Giannopoulou E, et al. Autophagy: novel action of panitumumab in colon cancer. Anticancer Res. 2009 Dec;29(12):5077-82. PMID: 20044619.. . .
CAS Number: 339177-26-3
Molecular Weight: (144.32 kDa)
Compound Purity: 98.80
Research Area: Cancer
Solubility: H2O
Target: EGFR
English
Deutsch
